BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30794824)

  • 21. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silica-coated iron oxide nanoparticles as a novel nano-radiosensitizer for electron therapy.
    Fathy MM; Fahmy HM; Saad OA; Elshemey WM
    Life Sci; 2019 Oct; 234():116756. PubMed ID: 31419444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization.
    Kudryavtsev VA; Khokhlova AV; Mosina VA; Selivanova EI; Kabakov AE
    PLoS One; 2017; 12(3):e0173640. PubMed ID: 28291803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition.
    Schilling D; Garrido C; Combs SE; Multhoff G
    Cancer Lett; 2017 Apr; 390():146-152. PubMed ID: 28108313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
    Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations.
    Raju U; Nakata E; Yang P; Newman RA; Ang KK; Milas L
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):886-94. PubMed ID: 12377342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Hsp90: a multitarget approach to radiosensitization.
    Camphausen K; Tofilon PJ
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4326-30. PubMed ID: 17671112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of pseudolaric acid A as a new Hsp90 inhibitor uncovers its potential anticancer mechanism.
    Liu J; Wu XD; Li W; Yuan Z; Yang K; Zhao QS
    Bioorg Chem; 2021 Jul; 112():104963. PubMed ID: 33991836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer.
    Zhang L; Yu Z; Wang Y; Wang X; Zhang L; Wang C; Yue Q; Wang X; Deng S; Huo X; Tian X; Huang S; Zhang B; Ma X
    Oncotarget; 2016 Nov; 7(47):76551-76564. PubMed ID: 27384878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Tumor and Radiosensitization Effects of N-Butylidenephthalide on Human Breast Cancer Cells.
    Su YJ; Huang SY; Ni YH; Liao KF; Chiu SC
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370116
    [No Abstract]   [Full Text] [Related]  

  • 35. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin.
    Reichert S; Reinboldt V; Hehlgans S; Efferth T; Rödel C; Rödel F
    Radiother Oncol; 2012 Jun; 103(3):394-401. PubMed ID: 22560712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hsp90 inhibitor geldanamycin enhances the antitumor efficacy of enediyne lidamycin in association with reduced DNA damage repair.
    Han FF; Li L; Shang BY; Shao RG; Zhen YS
    Asian Pac J Cancer Prev; 2014; 15(17):7043-8. PubMed ID: 25227788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
    Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
    Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of iron oxide nanoparticles in the radiosensitization of human prostate carcinoma cell line DU145 at megavoltage radiation energies.
    Khoei S; Mahdavi SR; Fakhimikabir H; Shakeri-Zadeh A; Hashemian A
    Int J Radiat Biol; 2014 May; 90(5):351-6. PubMed ID: 24475739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.